A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 01 Mar 2012 Results published in the Journal of the European Academy of Dermatology and Venereology.
    • 02 Oct 2009 New trial record.
    • 09 Sep 2009 Primary endpoint 'Psoriasis Area and Severity Index' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top